Prevention of RSV Bronchiolitis: An Ethical Issue
- PMID: 38621157
- DOI: 10.1097/INF.0000000000004354
Prevention of RSV Bronchiolitis: An Ethical Issue
Conflict of interest statement
A.C.V. participated at advisory boards and has received consulting fees from Sanofi and Pfizer. A.V. participated at advisory boards sponsored by MSD. The other authors have no conflicts of interest to disclose.
References
-
- Mao Z, Li X, Dacosta-Urbieta A, et al.; for RESCEU investigators. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe. Vaccine. 2023;41:2707–2715.
-
- Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21:734–749.
-
- De Luca D, Sanchez-Luna M, Schettler K, et al. Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt. Lancet Reg Health Eur. 2023;34:100753.
-
- Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023;28:2300606.
-
- Evaluation of the effectiveness and impact of Nirsevimab in Galicia. Available at: https://www.nirsegal.es/en . Accessed February 18, 2024.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources